Your browser doesn't support javascript.
loading
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Nowakowski, Grzegorz S; Willenbacher, Wolfgang; Greil, Richard; Larsen, Thomas S; Patel, Krish; Jäger, Ulrich; Manges, Robert F; Trümper, Lorenz; Everaus, Hele; Kalakonda, Nagesh; Brown, Peter; Jørgensen, Judit Meszaros; Cunningham, David; Dell'Aringa, Justine; Fox, Brian; Rubio, Neus Domper; Kilavuz, Nurgul; Casadebaig, Marie-Laure; Manzke, Oliver; Munoz, Javier.
Afiliação
  • Nowakowski GS; Division of Hematology, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, 55902, USA. nowakowski.grzegorz@mayo.edu.
  • Willenbacher W; Internal Medicine, Hematology and Oncology Department, Innsbruck Medical University, Innsbruck, Austria.
  • Greil R; Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria.
  • Larsen TS; Salzburg Cancer Research Institute and Cancer Cluster, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Patel K; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Jäger U; Swedish Cancer Institute Hematology and Oncology Department, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.
  • Manges RF; Division of Hematology and Hemostseology, Medical University of Vienna, Vienna, Austria.
  • Trümper L; Parkview Health, Parkview Cancer Institute, Hematology Tumor Site, Fort Wayne, IN, USA.
  • Everaus H; Department of Hematology-Oncology, Universitätsmedizin Göttingen, Göttingen, Germany.
  • Kalakonda N; Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia.
  • Brown P; University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK.
  • Jørgensen JM; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Cunningham D; Aarhus University Hospital, Aarhus, Denmark.
  • Dell'Aringa J; The Royal Marsden Hospital, The Institute of Cancer Research, Sutton, Surrey, UK.
  • Fox B; Celgene International, Boudry, Switzerland.
  • Rubio ND; Celgene International, Boudry, Switzerland.
  • Kilavuz N; Celgene International, Boudry, Switzerland.
  • Casadebaig ML; Celgene International, Boudry, Switzerland.
  • Manzke O; Celgene International, Boudry, Switzerland.
  • Munoz J; Celgene International, Boudry, Switzerland.
Int J Hematol ; 115(2): 222-232, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34797531
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Anticorpos Monoclonais Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Anticorpos Monoclonais Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos